Significant OS Benefit with Glofitamab plus GemOx in Transplant-Ineligible Patients with Relapsed or Refractory DLBCL By Ogkologos - December 6, 2024 806 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the STARGLO study Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR FDA Approves Ziftomenib for Relapsed or Refractory Acute Myeloid Leukaemia with... November 20, 2025 GENIE Registry Identifies Cancer Types Enriched with KRASG12C Somatic Mutations January 18, 2021 EMA Recommends Extension of Therapeutic Indications for Olaparib to Patients with... July 17, 2024 Patient Guide on Immunotherapy Side Effects and Their Management Now Available... April 29, 2026 Load more HOT NEWS How Joining a Clinical Trial Helped Me Find Hope While Living... A peek behind the scenes: Just how are our funding decisions... Breast Cancer Patient Takes Silly Pictures During Each Radiation Treatment to... When Ellen Found Out There Was A Grieving Mother In The...
